糖蛋白的异常糖基化在前列腺癌中的研究进展  

Aberrant glycosylation in glycoproteins in prostate cancer

作　　者：刘家舟 潘家骅[1] 薛蔚[1] LIU Jiazhou;PAN Jiahua;XUE Wei(Department of Urology,Renji Hospital,School of Medicine,Shanghai Jiaotong University,Shanghai 200127,China)

机构地区：[1]上海交通大学医学院附属仁济医院泌尿科,上海200127

出　　处：《现代泌尿外科杂志》2022年第6期526-530,534,共6页Journal of Modern Urology

基　　金：国家自然科学基金(No.82072847)。

摘　　要：前列腺癌的临床诊疗面临缺乏可靠生物标志物的痛点。糖组学的发展揭示了糖基化在肿瘤发展中具有重要作用。研究发现前列腺癌的发展过程伴随着大量糖蛋白的异常糖基化修饰,提示糖蛋白的异常糖基化检测可为前列腺癌的生物标志物提供新思路。本文就糖蛋白异常糖基化在前列腺癌中的研究进展进行综述。There is currently an unmet clinical need for reliable biomarkers in the diagnosis and treatment of prostate cancer.Recent advances in glycomics and glycoproteomics have revealed the irreplaceable role of glycosylation in tumor development.Studies have shown that the progression of prostate cancer is accompanied by aberrant glycosylation in glycoproteins,indicating the detection of such aberrant glycosylation may provide new insights into clinical biomarkers in prostate cancer.Here we will review the research progress of aberrant glycosylation in glycoproteins in prostate cancer.

关 键 词：前列腺癌 糖蛋白类 糖基化 生物标志物 

分 类 号：R737[医药卫生—肿瘤]